Aribio to Present AR1001 Phase 3 Results in First Session at CTAD 2026 Opening
Selected as a Key Oral Presentation at CTAD
52-week Efficacy and Safety Results to Be Unveiled
Topline Results to Be Released Separately Upon Completion
Aribio announced on July 22 that the results of the global Phase 3 clinical trial (POLARIS-AD) for AR1001, its oral Alzheimer's disease treatment candidate, will be presented at the 19th Clinical Trials on Alzheimer's Disease conference (CTAD 2026) to be held in Boston, USA in November.
The Phase 3 trial results for AR1001 will be unveiled during the first oral presentation session on November 16, the opening day of the conference. The presentation will be delivered by Sharon Sha, Professor at Stanford University School of Medicine, who served as the global principal investigator for the Phase 3 trial.
The presentation will cover the topic "Global Phase 3 trial POLARIS-AD of AR1001 in Patients with Early Alzheimer's Disease: 52-Week Efficacy Results and Extension Study Safety."
POLARIS-AD is a global Phase 3 trial conducted at approximately 230 institutions in 13 countries, including the United States, Canada, Europe, Korea, and China, targeting 1,535 patients with early Alzheimer's disease. The 52-week dosing for the last patient was completed in June 2026, and the study is currently undergoing data cleaning, database lock, and statistical analysis.
At the conference, Aribio plans to announce the efficacy and safety outcomes of the 52-week double-blind study, analyses of the monotherapy group, primary endpoints and subgroups, as well as safety data collected from the extension study. The topline results will be released immediately after the analyses are completed, independent of the conference schedule. CTAD is an international academic conference focused on clinical development and regulatory strategies for Alzheimer's disease treatments and is a venue where significant clinical trial results are shared.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Aribio CEO Jeong Jaejoon stated, "After presenting at CTAD, we plan to pursue new drug application procedures through consultations with global regulatory agencies, based on the primary clinical results."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.